Tag: Farawave
AVANT GUARD data reveal benefits of pulsed field ablation and may instigate shift...
This advertorial is sponsored by Boston Scientific.
Following the presentation of new data from the AVANT GUARD pivotal trial at the 2026 Heart Rhythm Society (HRS) annual meeting (23–26...
New data reaffirm safety and effectiveness of Boston’s Farapulse PFA platform...
A late-breaking presentation at the annual congress of the European Heart Rhythm Association (EHRA; 12–14 April 2026, Paris, France) has reaffirmed the safety and...
Second phase of Boston’s ADVANTAGE AF study meets primary safety and...
Boston Scientific has announced positive 12-month primary endpoint results from the second phase of the ADVANTAGE AF clinical trial evaluating the use of the...
Boston Scientific obtains CE mark for next generation of cardiac mapping...
Boston Scientific Corporation has announced it has received CE-mark approval for its navigation-enabled Farawave Nav ablation catheter in the treatment of paroxysmal atrial fibrillation...
Boston Scientific launches next generation of cardiac mapping for Farapulse PFA...
Boston Scientific Corporation has announced that it has received US Food and Drug Administration (FDA) approval of the navigation-enabled Farawave Nav ablation catheter for...